Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The treatment of hematologic malignancies with single or double umbilical cord blood unit transplantation followed by graft-versus-host prophylaxis with tacrolimus and mycophenolate mofetil.

Trial Profile

The treatment of hematologic malignancies with single or double umbilical cord blood unit transplantation followed by graft-versus-host prophylaxis with tacrolimus and mycophenolate mofetil.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin; Cyclophosphamide; Filgrastim; Filgrastim; Fludarabine; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Adverse reactions

Most Recent Events

  • 20 May 2014 Biomarkers information updated
  • 14 May 2012 Actual patient number changed from 7 to 6 as reported by ClinicalTrials.gov.
  • 14 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top